Short Interest in Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Drops By 48.6%

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 1,900 shares, a drop of 48.6% from the March 15th total of 3,700 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily trading volume, of 13,600 shares, the short-interest ratio is currently 0.1 days.

Scinai Immunotherapeutics Stock Performance

SCNI stock traded up $0.14 during mid-day trading on Wednesday, reaching $2.06. The company had a trading volume of 1,724 shares, compared to its average volume of 276,769. Scinai Immunotherapeutics has a one year low of $1.90 and a one year high of $8.92. The stock has a market capitalization of $1.92 million, a P/E ratio of -0.01 and a beta of 2.68. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.06. The stock’s 50-day simple moving average is $3.10 and its two-hundred day simple moving average is $3.33.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.